Company Overview

Drugs Made In America Acquisition II Corp. (DMII) is a U.S.-based special purpose acquisition company (SPAC) formed to identify, acquire, or merge with a business operating in the pharmaceutical, biopharmaceutical, or healthcare manufacturing sectors, with a strategic emphasis on domestic drug production. As a blank-check company, DMII does not conduct commercial operations or generate operating revenue; its sole business purpose is to complete a business combination within a defined timeframe following its initial public offering.

The company was established as a successor vehicle to Drugs Made In America Acquisition Corp., reflecting a continued strategy to support onshoring and near-shoring of pharmaceutical manufacturing and supply chains within the United States. DMII’s positioning centers on addressing national supply chain resilience, regulatory familiarity with the U.S. Food and Drug Administration, and growing policy and customer support for domestically manufactured pharmaceuticals.

Business Operations

DMII has no operating business activities, products, or services. Its operations are limited to organizational activities, capital raising, regulatory filings, target evaluation, and merger execution, consistent with the SPAC structure. Funds raised in its public offering are held in a trust account and may only be used to consummate a qualifying business combination or to redeem public shares.

The company’s operational focus involves identifying private or public target companies with established or emerging pharmaceutical manufacturing capabilities, particularly those aligned with U.S.-based production, generic drugs, essential medicines, or contract development and manufacturing services. Data inconclusive based on available public sources as to whether DMII completed a merger or liquidation as of the latest publicly filed disclosures.

Strategic Position & Investments

DMII’s strategic direction is oriented toward acquiring a controlling interest in a healthcare or pharmaceutical manufacturing company that benefits from domestic production trends, regulatory clarity, and supply chain security initiatives. The company has publicly articulated an interest in businesses that already generate revenue or are near commercialization, rather than early-stage research entities.

As a SPAC, DMII does not hold operating investments or portfolio companies prior to completing a transaction. No confirmed acquisitions, majority investments, or joint ventures have been publicly verified across available SEC filings and major financial publications. If a business combination was pursued or terminated, public disclosures indicate that details remain incomplete or conflicting across sources.

Geographic Footprint

DMII is headquartered in the United States and is incorporated under U.S. corporate law. Its geographic footprint is currently administrative rather than operational, limited to corporate offices and regulatory jurisdictions associated with U.S. capital markets.

Strategically, the company’s intended investment focus is on businesses with operations primarily in North America, particularly the United States, though potential targets may have international sourcing, sales, or distribution footprints. No verified international subsidiaries or operating facilities are attributable to DMII itself.

Leadership & Governance

DMII is led by an executive team and board with experience in healthcare, pharmaceuticals, capital markets, and public company governance. Leadership continuity with the sponsor’s prior SPAC vehicle is a defining characteristic, reinforcing sector specialization and transaction execution experience.

Key executives and directors include:

• Kyle D. Kingsley, M.D. – Chairman and Chief Executive Officer
• Neal C. Bradsher – Chief Financial Officer
• Michael S. Howe – Director
• Douglas W. Moore – Director

The leadership’s stated philosophy emphasizes disciplined capital deployment, regulatory compliance, and alignment with long-term public shareholders. Certain executive roles and tenures vary slightly across public disclosures; where inconsistencies exist, data inconclusive based on available public sources.